Preoperative GLP-1 use shows no extra aspiration risk and lower 14-day mortality in records analysis
A large records study found no sign that GLP-1 drugs raise anesthesia aspiration risk, but it cannot prove cause and effect and does not change how any surgery is managed.
Adults with type 2 diabetes who were taking a GLP-1 receptor agonist before surgery did not have a higher rate of aspiration under anesthesia than patients taking three other classes of diabetes drugs, and they died within 14 days of surgery less often than patients taking metformin or DPP-4 inhibitors, according to an observational analysis published August 12, 2026, in the journal Anesthesiology [1][2].
What the study looked at
Researchers led by Una E. Choi used the TriNetX Research Network, an electronic health record database, and examined surgeries performed between June 1, 2013, and June 1, 2023. That period came before the 2023 American Society of Anesthesiologists guidance advising clinicians to hold GLP-1 receptor agonists before surgery [1][2].
All patients were adults with type 2 diabetes who received anesthesia. They were matched 1:1 on surgery type, patient characteristics, diabetes biomarkers and risk factors for problems after surgery. GLP-1 use was compared with metformin, with SGLT2 inhibitors, and with DPP-4 inhibitors. Patients taking the comparator drug at the same time were excluded from the comparison [1][2].
The team tracked eight outcomes in the 14 days after surgery: death, aspiration pneumonitis (lung inflammation from inhaled stomach contents), bacterial pneumonia, emergency intubation, acute kidney injury, stroke, heart attack, and a composite of death, heart attack or stroke [1][2].
The numbers
Compared with metformin, patients on a GLP-1 receptor agonist died within 14 days in 0.98% of cases versus 2.20%, a risk ratio of 0.44 (95% confidence interval 0.31 to 0.64; adjusted P value 0.0002) [1][2].
Compared with DPP-4 inhibitors, deaths were 1.84% versus 2.89% (risk ratio 0.63, 95% confidence interval 0.45 to 0.89; adjusted P value 0.04), and bacterial pneumonia occurred in 0.85% versus 1.80% (risk ratio 0.47, 95% confidence interval 0.29 to 0.76; adjusted P value 0.02) [1][2].
Against SGLT2 inhibitors, the combined cardiovascular measure was 3.86% versus 5.03% (risk ratio 0.77, 95% confidence interval 0.60 to 0.98). The adjusted P value was 0.13, and the authors described that finding as a numerical difference rather than a statistically significant one [1][2].
On aspiration, the authors concluded there was "no increased aspiration risk compared to any other drug class" [1]. The abstract does not list the aspiration-pneumonitis rates behind that conclusion [2].
Why it matters for patients
The concern behind the 2023 guidance is that GLP-1 drugs slow stomach emptying, which could raise the chance of food or liquid coming back up during anesthesia and entering the lungs [1]. This analysis of records from before that guidance found no sign of extra aspiration risk, and it found lower 14-day death rates than two of the three comparator classes [1][2].
Several limits matter. This is an observational database analysis, so it can show associations but cannot prove that the drugs caused the better outcomes. The authors write that confirmation in prospective studies is needed before the findings guide management [1][2]. The analysis covers the GLP-1 receptor agonist class as a whole; the abstract does not specify which individual drugs were included, at what doses, or how long before surgery patients stopped taking them. Whether the results apply to people using these medicines for weight loss rather than type 2 diabetes has not been reported [1][2]. Decisions about holding a GLP-1 before a procedure, and for how long, remain with the anesthesia and prescribing team.
What happens next
The authors call for prospective studies to confirm the findings before they inform evidence-based management strategies [1][2]. No specific follow-up trial or revised professional guidance is announced in the paper's abstract. The article appears ahead of print, so the final version will be assigned to a print issue later [1].
People with upcoming surgery who take semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) or another drug in this area should expect the question of whether to pause the medication to be settled by their care team, not by this study on its own.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.